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Abstract 
Objectives: To explore the experience of treatment decision-making (TDM) amongst men diagnosed 
with stage 1-3 prostate cancer.  
Methods: Mixed-methods study incorporating UK wide cross-sectional postal survey of men 18-42 
months post-diagnosis and semi-structured interviews with a subsample (n=97), including men who 
received both radical treatments and active surveillance. Interview data was analysed using a 
Framework approach.  
Findings: Within the context of TDM, ‘drivers’ included men’s preferences for decision-making 
responsibility or clinical direction, relative treatment intrusiveness or desire for excision, and work, 
personal and social life priorities; ‘facilitators’ were mechanisms such as shared decision-making 
utilised by clinicians to enact, but also sometimes challenge drivers. Drivers and facilitators can 
conflict, challenging patient empowerment. Men frequently undertook greater TDM responsibility 
than they desired, with no clinical recommendations; others reported receiving conflicting clinical 
recommendations. Information on potential side effects was often reported as inadequate. 
Unchallenged preferences, absence of clinical recommendations and inadequate preparation for 
side effects sometimes led to decision regret.  
Conclusions: TDM should involve men exercising preferences and priorities in discussion with 
clinicians. Men are not empowered when required to take more TDM responsibility than desired or 
when their potentially inappropriate preferences are unchallenged. Clinicians should ensure patients 
do not receive conflicting recommendations.   
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1. INTRODUCTION 
Prostate cancer (PCa) is the most common form of cancer amongst men in the UK and developed 
countries, with 10-year survival rates of ≥84%[1]. The high probability of long-term survival makes 
health-related quality of life (HRQoL) a priority. Men diagnosed with localised (stage I-II) and locally 
advanced (stage III) PCa are often offered  a range of potential treatment choices, including radical 
prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), adjuvant androgen 
deprivation therapy (ADT), active surveillance (AS), or combinations of these (i.e. EBRT and ADT). 
Newer treatments such as cryotherapy and high intensity focussed ultrasound (HIFU) have limited 
availability. The treatment decision-making (TDM) process for men diagnosed with PCa is particularly 
difficult, as current clinical and pathological features are limited in their ability to distinguish 
between inherently aggressive and indolent tumours[2], and there is currently no clear evidence to 
suggest one treatment is more effective than another[3].  
The commonly available treatment options all have side effects that can significantly impact upon 
the HRQoL of men, and may persist long-term[4,5]. These include sexual and urinary dysfunction 
following RP, bowel dysfunction, loss of libido and urinary irritations following EBRT, and 
gynecomastia, mood disturbances, weight gain, penile shrinkage, loss of libido and hot flushes 
following ADT. While AS avoids or delays active treatment and associated physical side effects, it has 
nevertheless been associated with anxiety over non-treatment and potential disease progression, 
and increasing urinary obstructive symptoms[6]. It is unclear whether the benefits of AS outweigh 
potential negative effects of treatment[7,8]. While most patients who choose active treatment 
accept side effects as consequences of treatment, when multiple, equally effective treatments are 
available, each with negative side effects, TDM can be dominated by significant uncertainty and 
anxiety[5].  
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This study, part of a UK-wide, patient-reported outcome (PRO) survey entitled Life After Prostate 
Cancer Diagnosis (LAPCD)[9], explored the experience of TDM amongst men diagnosed with stage I-
III prostate cancer.  
METHODS 
2.1 STUDY DESIGN 
LAPCD is a UK-wide population based mixed-methods study, incorporating a national postal survey 
and semi-structured telephone interviews with a purposively selected subsample[9]. In England, 111 
of 136 Trusts participated along with all Trusts/Health Boards in Northern Ireland, Scotland and 
Wales. Survey responses were first analysed with regards men’s self-reported involvement in TDM 
of men, and their experience then explored in greater depth through interviews. The research team 
worked in collaboration with a patient-user advisory group and clinical colleagues at all stages of the 
project. 
2.2 PARTICIPANTS AND SETTING 
Men alive 18-42 months following PCa diagnosis (ICD10 C61) in participating Trusts were identified 
through population-based cancer registries in England, Wales, Scotland and Northern Ireland, and 
mailed surveys from their treating Trust/Board. Completed surveys were returned to a survey 
provider, Picker Institute Europe, who managed the data. Men in England were surveyed December 
2015–March 2016, and in Scotland, Northern Ireland and Wales July–October 2016.  
Respondents indicated on the survey their willingness to be contacted and invited for interview. A 
purposive sampling framework was developed, stratified by treatment group (e.g. RP, EBRT, 
brachytherapy, ADT, and AS). We also included a range of men who indicated experience of either 
no problems or one or more physical (e.g. urinary incontinence, bowel problems and erectile 
dysfunction) and emotional problems (e.g. anxiety/depression). Participants included men from 
Black, Asian and Minority Ethnic groups and self-identified sexualities. Cross-sectional, semi-
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structured telephone interviews were conducted by four experienced researchers (JN, LM, CR and 
RW), across two universities in England between January-November 2016.  
2.3 MATERIALS 
The main LAPCD survey comprised eight sections, totalling 88 questions. Section Two “Your 
diagnosis and treatment” included a question about TDM involvement that asked patients: ‘Do you 
think your views were taken into account when the team of doctors and nurses caring for you were 
discussing which treatment you should have?’ Possible responses were: TDM1. ‘Yes, definitely’; 
TDM2. ‘Yes, to some extent’; TDM3. ‘No, my views were not taken into account’; TDM4. ‘I didn’t 
know my treatment was being discussed by a team of doctors/nurses’; TDM5. ‘Not sure/can’t 
remember’. A version of this question was validated as part of the PICKER Patient Experience 
Questionnaire[10], and has subsequently been incorporated, albeit in slightly altered versions, in 
each iteration of the National Cancer Patient Survey[11].  Immediately following this question in the 
LAPCD survey was the 5-item Decision Regret Scale[12] (DRS), for men to indicate levels of regret 
they felt regarding their treatment decision. These five items are combined to form a scale 0-100, 
with higher scores indicating greater decision-regret. Men’s responses to these questions informed 
analysis of their interview data. 
An interview topic guide was developed in collaboration with clinical colleagues and our patient/user 
group, and informed by previous evidence[13]. The guide comprised open-ended questions, each 
with several prompts. Amongst issues discussed, men were asked to describe their TDM experiences; 
how much information they had received about their condition, the extent to which they had 
wanted control or had felt in control of decision-making, whether they were treated as an equal 
partner in the process by clinicians and what influenced their treatment decisions.  
2.4 ANALYSIS 
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For this analysis we explored the TDM process described by men during their interviews and 
compared these with the response they provided to the TDM question in the survey. Interviews 
were transcribed verbatim and data uploaded into Nvivo v.11.2[14], and analysed using Framework-
Analysis; a matrix-based approach conducted through a series of stages[15,16]. The first stage 
involved familiarization, whereby researchers became immersed in the data and aware of key ideas 
and recurrent themes. Following each interview, researchers’ summarised key issues discussed and 
shared these amongst the research team for discussion. 
A thematic coding framework of emerging themes was then developed. An initial draft of the coding 
framework was tested against five interview transcripts. Four researchers (JN,CR,EW,RW) 
independently coded the same three transcripts, with codes then discussed. Several patient/user 
group members reviewed selected transcripts and provided feedback. The complete dataset was 
then indexed, identifying data that corresponded to particular themes. Double coding in Nvivo11 
was conducted by three authors (CR, EW and RW) on 10% of interviews, with final Kappa scores of 
≥80% across all themes for all researchers. Indexed data was then arranged in charts/matrices of 
themes, and key ideas and themes summarized in the charts/matrices with relationships between 
them identified. Extracts are provided to illustrate themes in the Findings section, with clinical and 
demographic characteristics of participants and responses to TDM and DRS questions. 
2.5 Ethics 
The study received the following approvals: Newcastle and North Tyneside 1 Research Ethics 
Committee (15/NE/0036), Health Research Authority Confidentiality Advisory Group (15/CAG/0110), 
NHS Scotland Public Benefit and Privacy Panel (0516-0364), and NHS R&D approval from Wales, 
Scotland and Northern Ireland. 
3. FINDINGS 
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In total, 35,823/58,930 (60.8%) men completed the survey. Of these, 26,808 (74.8%) were diagnosed 
at stage I-III. Interviews were conducted with 97 men (stage I-III) from across the UK. Table 1 shows 
participants’ demographic and treatment characteristics. The interview sample was younger than 
respondents to the survey only (mean 65.5 Vs. 71 years), more ethnically diverse, with a higher 
proportion of men on AS. Most interview participants were diagnosed at stage I (46.4%, n=45), EBRT 
with ADT was the most common treatment option (25.2%, n=26). 
3.1 SURVEY DATA 
Most study participants, both survey-only respondents and those interviewed (68.8% vs. 69.0%), 
indicated their views had ‘definitely’ been taken into account during the TDM process (Table 2). 
Further proportions of survey-only and interview participants (17.8% vs. 24.7%), indicated their 
views were ‘to some extent’ taken into account, which might suggest they were not fully involved 
with TDM. Very few (3.3% vs. 2.1%) indicated their views were ‘not taken into account’. Overall, in 
both samples the mean decision-regret reported amongst men who indicated their views were 
‘definitely’ taken into account was lower than for men whose views were given less consideration by 
clinicians (survey-only: 11.4 vs. 25.5; interview: 11.4 vs. 29.6).  
3.2 INTERVIEWS 
3.2.1 Comparing survey and interview data 
We compared the responses of individual participants to the survey TDM question with how men 
later described the process during interviews. Of the 67 men who indicated in the survey their views 
were ‘definitely’ taken into account, 12 described during subsequent interviews concerns with the 
TDM process and thought they had not been adequately involved (Table 3). Of the 26 men who 
indicated in the survey their views were only taken into account ‘to some extent’ or ‘were not taken 
into account’, almost half (n=12) reflected in their subsequent interview they were content with 
limited TDM involvement, while just over half (n=14) were not. 
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3.2.2 Factors associated with treatment decisions 
Several factors were identified in the interview data that shaped the TDM process, which have been 
categorised into three overarching themes: contextual; drivers, and; facilitators.  
3.2.3 Contextual factors 
Contextual factors structured the decision-making process and determined the treatment options 
available to men, shaping the potential for empowerment. Chief amongst these factors was the way 
in which men understood the stage of their disease and treatments available. 
He (urologist) told me what options there were and I asked, you know, was there any option 
of doing nothing? And he said: no, your cancer needs treatment and so you’ve really got to 
decide, you know, which way you want to go. And I was satisfied there were two treatments 
that stood a good chance of being successful.  
(66 years, Stage III, RP: TDM1, DRS 45)  
Comorbidities and previous medical history influenced available options, and while one man 
understood his irritable bowel syndrome precluded surgery, another described how adhesions from 
previous abdominal surgery ruled out both surgery and radiotherapy. Men with prior knowledge of 
cancer or clinical backgrounds better understood available treatment options and side effects, 
finding it easier to participate in TDM. Locally available treatment options varied and men in rural 
areas especially and Northern Ireland reported limited access to robotic prostatectomy, 
brachytherapy and newer treatments.  
3.2.4 Driver factors   
Driver factors represented men’s specific preferences with regards both their involvement in the 
TDM process and for specific treatments. These factors were closely related to an intra-personal 
process men underwent in adapting and responding to their new situation. It was apparent that for 
many men the prospect of having to decide their cancer treatment was complex, onerous and ‘very, 
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very difficult for an ordinary guy’, in what was described by one as ‘the most stressful stage’ of his 
treatment journey. Many men stated they had wanted more direction from clinicians, and several 
said they found it ‘odd’ and ‘daunting’ to be expected to choose their own treatment, given no 
clinical knowledge; some asking how they could ever know whether they made the right decision. 
I was annoyed that I wasn’t advised the best treatment, [and] that I had to decide. The 
decision should have been made for me in the best treatment and for me to go in and [the 
consultant] say, right this is the treatment you are going to get, rather than being asked 
what treatment I would prefer. So I don’t know whether it’s been the right treatment or not. 
    (74 years, Stage II, EBRT + ADT: TDM2; DRS missing) 
Indeed, many more study participants indicated they would have preferred greater clinician 
direction than wanted more autonomy. Some men wanted only to be consulted about treatments 
clinicians favoured, and be fully informed about potential side effects (I accepted [the treatment] 
because that was what the doctor recommended. I was happy with that). Nevertheless, while for 
some men involvement in the TDM process was unwelcome, others reported taking control of 
treatment decisions increased psychological well-being. 
I’m sort of quite at peace with this [decision] at the moment, as a result of the fact that I feel 
I’ve taken as much control of this [TDM process] as I can, by accessing what I consider to be 
good quality services. … [It] has been probably the most positive part of my experience so far. 
     (58 years, Stage I, EBRT+ADT: TDM 2; DRS 0)  
Other driver factors informed patient’s specific treatment preferences. These included the patient’s 
priorities with regards work, social life and HRQoL and the relative intrusiveness of treatments, 
previous experience of family/friends with particular treatments, and expected treatment side-
effects. The most common Drivers for surgery were an apparent visceral desire to ‘get rid of the 
cancer’, that as a treatment modality it was quickly completed, or left open opportunities for further 
treatments, such as radiotherapy. The most common driver for either radiotherapy or brachytherapy 
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was a perception it was less ‘intrusive’ or ‘invasive’. Active surveillance, often interchangeably 
described as ‘watch & wait’, ‘wait & see’ or ‘active monitoring’ was favoured when patients 
preferred to ‘let sleeping dogs lie’, believed ‘the cure could be worse than the disease’, or were 
simply undecided: ‘I’ll stick with just the monitoring as I’m not sure what treatment is best.’  
3.2.5 Facilitator factors 
Facilitating factors were those associated with an inter-personal dimension of communication and 
SDM between clinicians, men and their partners. Facilitating factors could empower men to make 
informed treatment decisions that incorporated their preferences and priorities. Facilitators 
included availability of easily understood information about treatment options, potential side-effects 
and their likely severity and a few men mentioned treatment decision aids, such as DVDs.  
I got quite a lot of information from the hospital on diagnosis and stuff which was very 
useful, very, very comprehensive explanation, sharing information, discussing the pros and 
cons of surgery and any other interventions.   (54 years, Stage I, RP: TDM1; DRS 0) 
Facilitators that enabled men to fulfil their optimum information needs included access to specialist 
staff, an environment in which men did not feel rushed by clinicians eager for them to make 
decisions, and access to the lived experience of men who had previously experienced treatments. 
Partners, where involved, were valued for their role as a ‘sounding board’ for men to discuss 
treatment options, and often took responsibility for researching options. However, many of the 
concerns regarding TDM raised by men in the study concerned an absence of facilitators. In 
particular, men who were unhappy with the TDM process frequently described not being fully 
informed of potential treatment effects, and were thus unprepared to manage them.  
I wasn’t prepared at all. I wasn’t. I just thought it was, you know, it will be done and 
everything will be OK. ... I think I made the wrong decision definitely. I think there should be 
a lot more explanation of, you know, what’s actually happening and what can happen before 
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you’re actually having your surgery or you’ve had your radio treatment, whatever, it should 
be explained a lot, a bit clearer. Not just a pamphlet and say, ‘Read that’. You should be sat 
down and said ‘This is what can happen’.  (63 years, Stage II, RP: TDM4, DRS 95) 
3.2.6 Conflicts between TDM factors  
Conflicts that inhibited expression of men’s preferences and priorities (drivers) limited autonomy, 
while conflicts that inhibited communication and knowledge sharing (facilitators) reduced men’s 
ability to make informed decisions. Contextual factors inhibited drivers when particular patient 
priorities or preferences for certain treatments, often influenced by previous experiences of friends 
or family, were hindered by their limited availability. 
Given experiences of people I know I was told that radiotherapy had quite an adverse effect 
on you so that’s the reason why I was opting for surgery. However, …the surgeon who did 
the keyhole surgery had moved…back to England and the only surgeon that I spoke to said 
that keyhole surgery was not an option over here [N Ireland] now plus the fact that it was 
open surgery which would have quite serious consequences for a man of my age, so then 
that’s when I opted for radiotherapy.  (70 years, Stage I, EBRT: TDM 1; DRS 20) 
Drivers and facilitating factors conflicted when a man’s preference for delegating TDM to clinicians 
(driver) was overruled by being reportedly expected to take the lead in TDM, with potential 
consequences for men’s emotional wellbeing.  
‘The problem is I’ve asked them [clinicians] about treatments and the best treatment and 
they haven’t been able to give me an answer. … They say it’s up to me to decide which 
treatment I want. Unfortunately, because I’m not qualified in that area I can’t give an 
opinion on that, so I’m a bit in limbo [about] which is the best treatment. … I’m very, very 
depressed about it.’    (67 years, stage I, AS: TDM2; DRS 30) 
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Being provided only with facts about treatments and then expected to decide was insufficient for 
many men to be comfortable in their treatment decision, and specific recommendations were 
frequently requested from clinicians. When one clinician would not provide a man with a treatment 
recommendation, he described any choice he made as a ‘gamble’. 
‘I was given the facts of the thing and I said: if you were sitting where I’m sitting, the doctor, 
and I was sitting where you were sitting, what would your advice be? He said: it’s not me, it’s 
you. He wouldn’t commit himself so the way it ended up, I had to make the decision.’  
     (79 years, stage I, EBRT+ADT: TDM1; DRS 30) 
 
Whether or not men wanted TDM responsibility, conflicting clinical advice about appropriate 
treatment options frequently left them confused rather than empowered. 
‘One [consultant] was very much open it up, get rid of it and cut it out and then you know 
it’s gone, … and the other was more gentle and he said well actually, radiotherapy has a 
pretty high success rate and in your case I don’t think there’s any need for surgery. …. That’s 
how it was, being passed from one consultant to another.’   
(69 years, stage I, EBRT+ADT: TDM1; DRS 30) 
Drivers could be compromised retrospectively by an apparent failure of facilitators when men who 
had completed treatment described becoming aware of treatment options additional to those 
offered to them. These treatments may not have been appropriate, but the possibility they may 
have been but were not discussed during TDM added to men’s uncertainty. In contrast, one man’s 
strong unchecked treatment preference led him to have surgery, despite clinical advice to remain on 
AS, and he reported significant subsequent decision regret when treatment side-effects were more 
severe than expected.   
DISCUSSION AND CONCLUSION 
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4.1 Discussion 
This study categorised the primary factors that shaped the TDM process of men diagnosed with 
localised and locally advanced PCa, in a cross-sectional UK-wide sample. The mixed-methods 
approach allowed a nuanced understanding of the way in which men viewed their actual and 
preferred TDM involvement, and their associated levels of decision-regret.  Some men desired less 
involvement, though some then regretted treatment effects, others reported their views were 
‘definitely’ taken into account but nevertheless identified concerns with the TDM process. Men’s 
accounts indicated the way in which clinicians communicated with them could either inhibit their 
preferences for TDM delegation or leave them confused with conflicting recommendations. Many of 
the themes identified here resonate with findings reported in previous studies[17]. Recent 
systematic reviews have synthesised qualitative research on men’s use of information to make 
decisions about PCa treatment options[18], and how couples approach TDM[19]. Previous research 
in PCa has investigated the influence on TDM of previous family and friends’ experience of PCa[20], 
personal history factors[21], psychological factors[22], patient priorities for treatment decisions[23], 
treatment-related beliefs[24], and personality traits[25]. 
A full spectrum of patient involvement with TDM was reflected by study participants, from passive 
acceptance of paternalistic clinical decisions to adoption of an agency model whereby clinicians 
educate patients who then make decisions alone. Study participants expressed different preferences 
for TDM responsibility, but while policy states clinicians should elicit the level of TDM involvement 
patients want[26,27], a sizable proportion of study participants reported they had been expected to 
take more responsibility than desired. Arguably, men may have not received sufficient information 
prior to TDM involvement, and evidence indicates patients have limited knowledge of cancer prior to 
diagnosis[28]. The survey question did not elicit data on how well informed men were prior to TDM 
involvement, but previous evidence indicates preference for TDM involvement increases the more 
individuals are informed[28]. Clinicians frequently underestimate the amount of information 
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patients want[17], and may sometimes expect them to engage in TDM prematurely. It is therefore 
essential, once patients’ initial information needs are met, for clinicians to elicit their desired level of 
TDM involvement. 
However, some men may prefer less information on treatment options if they have already 
established a preference[29], while others may only wish to be ‘consulted’ on treatment decisions 
already favoured by clinicians. If patient empowerment involves patients setting strategies to 
achieve their own goals, then a preference to delegate TDM responsibility does not necessarily 
entail disempowerment[30]; rather it represents an ‘autonomous choice of dependency’[31]. Indeed, 
requiring patients to take more TDM responsibility than they desire may be to disempower them. 
Recent evidence indicates incongruence between preferred and actual roles in TDM led to 
significantly lower health-related quality of life amongst PCa survivors, especially amongst men who 
reported more involvement than desired[32].  
Clinicians’ recommendations remain the most consistent factor influencing patients’ TDM[22], and 
many more of our study participants indicated they would have preferred greater clinician direction 
than wanted more autonomy. However, some patients doubt the objectivity of information received 
from physicians and want validation from other clinicians[18]. Men wanting active TDM involvement 
were empowered by adequate facilitating factors, such as easily understandable information and 
good communication with clinicians[33], which is tailored to their individual preferences for TDM 
involvement. This would be facilitated via routine use of patient decision aids[28]. 
Men were potentially disempowered when information was absent[34], or when they received 
conflicting treatment recommendations. In particular, our findings highlighted the importance of 
patient preparation for potential side effects, and their possible severity, as a fundamental pre-
requisite for participating in TDM for PCa. The involvement of partners as information seekers and 
synthesisers was important, especially given patients forget between 40-80% of information given 
during consultations[35]. While men may feel empowered when making decisions based upon 
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certain drivers for treatment choice, they sometimes later regretted decisions if clinical advice 
(facilitating factor) indicating their choice might be inappropriate was ignored. Previous studies have 
found approximately 16% of participants expressed regret regarding their PCa treatment choice[30], 
and if side effects are severe, men may regret their choice whether or not they were actively 
involved in TDM[30]. Nevertheless, higher levels of decision-regret are significantly associated with 
higher levels of decisional conflict[36], which might be caused by an absence of facilitators, or 
receiving conflicting treatment recommendations from clinicians, or being expected to take more 
TDM responsibility than desired. 
4.2 Limitations 
This is a retrospective study, 2-3 years following PCa diagnosis, and recall bias may be present. 
Potential interviewer bias was mitigated with use of open-ended questions.   
4.3 Conclusions 
This study identified ways in which the interaction between three categories of factors, context, 
drivers and facilitators, can enhance or inhibit mens’ experience of TDM involvement following a PCa 
diagnosis. Patient-centred care requires men to be free to articulate and enact their preferences and 
priorities. For clinicians to effectively facilitate TDM involvement they should acknowledge men’s 
preferences and provide tailored clinical information. TDM failed when men were unable to exercise 
preferences and priorities or clinicians failed to adequately facilitate them.  
4.3 Practice implications  
The TDM process has potential long-term impact on the HRQoL of men diagnosed with PCa, but men 
differ in the level of TDM involvement they want. Men should therefore have the opportunity to be 
informed of exactly which appropriate treatment options are available and why others are not, and 
the prevalence and potential severity of associated side effects. Use of patient decision aids should 
be encouraged. However, some men desire greater direction from clinicians about the most 
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appropriate treatments, and where possible this should be respected. Expecting men to take greater 
TDM responsibility than desired can for some men inhibit rather than facilitate patient 
empowerment. All clinicians involved in a patient’s care should be cognizant of each other’s views 
and ensure patients do not receive conflicting recommendations. Men with firm treatment 
preferences should be encouraged to discuss these with clinicians to prevent potential subsequent 
decision regret.  
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Table 1: Demographic and treatment characteristics of surveyed and interviewed men 
Characteristic  Survey 
(n=26,808, 100%) 
Interviews 
 (n=97, 100%) 
Age Mean (range) 71.09 (41-98) years 65.5 (48-87) years 
Nation England 23,001 (85.8%) 71 (78.0%) 
Wales 1,861 (6.9%) 10 (10.3%) 
Scotland 1,103 (4.1%) 6 (6.2%) 
Northern Ireland 843 (3.1%) 10 (10.3%) 
Disease stage I 10,880 (30.4%) 45 (46.4%) 
II 8,719 (24.3%) 28 (28.9%) 
III 7,209 (26.9%) 24 (24.5%) 
Marital Status Married/ Civil partnership  21,187 (80.0%) 68 (70.1%) 
Separated/Divorced  1,970 (7.4) 6 (6.2%) 
Widowed  1,946 (7.4%) 2 (2.1%) 
Single  1,023 (3.9%) 12 (12.4%) 
Other  358 (1.4%) 9 (9.2%) 
Sexual Orientation Heterosexual  24,966 (93.1%) 83 (85.6%) 
Homosexual  213 (0.8%) 13 (13.4%) 
Other 526 (2.0%) 0 (0.0%) 
Missing 1,103 (4.1%) 1 (1.0%) 
Ethnicity White 25,180 (96.8%) 87 (89.6%) 
Black British 410 (1.6%) 9 (10.3%) 
Other 413 (1.6%) 1 (2.1%) 
Treatment EBRT + ADT 6,047 (26.7%) 26 (25.2%) 
Active surveillance 2,399 (10.6%) 25 (24.3%) 
Surgery only 5,929 (26.1%) 23 (23.7%) 
ADT Only 1,452 (6.4%) 6 (6.2%) 
EBRT only 2,106 (9.3%) 5 (5.2%) 
Surgery + EBRT/ADT 1,654 (7.3%) 6 (6.2%) 
Other  4450 (16.6%) 6 (6.2%) 
Overall survey %s relate to proportion of men at stage I, II or III. An additional 3,925 men had stage 
IV disease at diagnosis and 5,090 were missing stage at diagnosis information from cancer 
registration records. ‘Other treatment’ includes systemic treatments, HIFU, unknown radiotherapy, 
follow-up unknown, no treatment or other combination not otherwise listed. ‘Other sexuality’ 
includes bisexual, don’t know and prefer not to answer. ‘Other marital status’ was left up to men to 
determine, but included in the interview sample men who had partners who were not married or in 
a civil partnership. 
EBRT External Beam Radiotherapy; ADT Androgen deprivation therapy.  
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Table 2: Survey responses of surveyed and interviewed men to involvement in TDM question and Decision Regret Score:  
Question Items ‘Yes, definitely’ 
 
‘Yes, to some extent’ 
 
‘No, my views were 
not taken into 
account’  
‘Didn’t know treatment 
was being discussed’ 
 
‘Not sure’  
  Survey Interviews  Survey Interviews  Survey  Interviews  Survey  Interviews  Survey  Interviews  
TDM 
Involvement  
No. men 
(%) 
 
18,907 
(68.8) 
67  
(69.0) 
4,670 
(17.8) 
24  
(24.7) 
879 
(3.3) 
2  
(2.1) 
877 
(3.3) 
3  
(3.0) 
909 
(3.5) 
0 (0.0) 
Decision 
Regret Score 
Mean  
(SD) 
11.4 
(14.2) 
11.4  
(15.2) 
25.5 
(18.4) 
29.6  
(20.7) 
31.9 
(23.6) 
37.5  
(53.0) 
27.5 
(20.1) 
58.3  
(33.3) 
25.7 
(18.3) 
0 (0.0) 
Median 
(IQR) 
5  
(0-20) 
5  
(0-20) 
25  
(10-35) 
32.5 
(10-40) 
30 
(15-50) 
37.5  
(0-75) 
25  
(10-40) 
50  
(30-50) 
25  
(10-40) 
0 (0.0) 
Range 0-100 0-80 0-100 0-65 0-100 0 - 75 0-100 30-95 0-100 0 (0.0) 
Survey n = 26,291 men completing the TDM question (98.1% of respondents at stage I-III). Interview n = 97 men 
SD Standard Deviation. IQR Inter quartile range.  
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Table 3: Retrospective reasons given in interviews for lack of decision-making satisfaction amongst men who had indicated in the survey their views had 
‘definitely’ been taken into account 
Pt No. Stage Tx Lack of info  
tx 0ptions 
Lack of info  
side effects 
Felt 
rushed  
No HCP Tx   
recommendations  
1SG02AX09 1 EBRT X    
1SG03AX24 1 ADT/AM    X 
1SG04AX05 1 AM X    
5SG01BX03 1 RP  X   
2SG08XX19 1 AM X    
1SG04BX16 2 ADT X    
1SG04BX28 2 AM X X  X 
4SG08XX06 2 RP   X  
5SG03B104 2 HT  X   
2SG09XX08 3 RP X X   
2SG09XX03 3 RP X X X X 
1SG03AX26 3 ADT    X 
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Table 4: Categorised factors that influence Treatment decision-making (TDM) 
Categories Themes 
Contextual factors How patients understand their condition 
Comorbidities and previous medical history 
Patient knowledge and understanding of cancer 
Geographical availability of treatments 
Drivers  Preference for involvement in TDM 
Priorities for work/ lifestyle  
Treatment preferences or ‘let sleeping dogs lie’ 
Previous experience of friends and family  
Perception of certain treatments as ‘intrusive’/ ‘invasive’ 
Facilitators Information regarding treatment options 
Information regarding treatment side effects (severity/prevalence 
Treatment Decision Aids (TDAs) 
Involvement of partners 
Access to lived experience of previously treated men 
Unrushed environment 
 
 
 
 
 
 
